Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 30:68:e230314.
doi: 10.20945/2359-4292-2023-0314. eCollection 2024.

Clinical screening for GCK-MODY in 2,989 patients from the Brazilian Monogenic Diabetes Study Group (BRASMOD) and the Brazilian Type 1 Diabetes Study Group (BrazDiab1SG)

Affiliations

Clinical screening for GCK-MODY in 2,989 patients from the Brazilian Monogenic Diabetes Study Group (BRASMOD) and the Brazilian Type 1 Diabetes Study Group (BrazDiab1SG)

Renata Peixoto-Barbosa et al. Arch Endocrinol Metab. .

Abstract

Objectives: To evaluate the accuracy of routinely available parameters in screening for GCK maturity-onset diabetes of the young (MODY), leveraging data from two large cohorts - one of patients with GCK-MODY and the other of patients with type 1 diabetes (T1D).

Materials and methods: The study included 2,687 patients with T1D, 202 patients with clinical features of MODY but without associated genetic variants (NoVar), and 100 patients with GCK-MODY (GCK). Area under the receiver-operating characteristic curve (ROC-AUC) analyses were used to assess the performance of each parameter - both alone and incorporated into regression models - in discriminating between groups.

Results: The best parameter discriminating between GCK-MODY and T1D was a multivariable model comprising glycated hemoglobin (HbA1c), fasting plasma glucose, age at diagnosis, hypertension, microvascular complications, previous diabetic ketoacidosis, and family history of diabetes. This model had a ROC-AUC value of 0.980 (95% confidence interval [CI] 0.974-0.985) and positive (PPV) and negative (NPV) predictive values of 43.74% and 100%, respectively. The best model discriminating between GCK and NoVar included HbA1c, age at diagnosis, hypertension, and triglycerides and had a ROC-AUC value of 0.850 (95% CI 0.783-0.916), PPV of 88.36%, and NPV of 97.7%; however, this model was not significantly different from the others. A novel GCK variant was also described in one individual with MODY (7-44192948-T-C, p.Ser54Gly), which showed evidence of pathogenicity on in silico prediction tools.

Conclusions: This study identified a highly accurate (98%) composite model for differentiating GCK-MODY and T1D. This model may help clinicians select patients for genetic evaluation of monogenic diabetes, enabling them to implement correct treatment without overusing limited resources.

Keywords: MODY; diabetes mellitus; genetic techniques; glucokinase; type 1 diabetes.

PubMed Disclaimer

Conflict of interest statement

Disclosure: the authors declare no conflicts of interest in connection with this article. A full list of the member roster and investigators of the BRASMOD and BrazDiab1SG studies is provided in the Supplementary Material.

Figures

Figure 1
Figure 1. (A) Receiver-operating characteristic (ROC) curves of predictors significantly discriminating between GCK maturity-onset diabetes of the young (GCK-MODY) and type 1 diabetes and (B) between GCK-MODY and clinical maturity-onset diabetes of the young (MODY) without detected variants (NoVar). The dots plotted inside each curve in Panels A and B represent J points (maximum distance from the diagonal line). (C) Area under the ROC curve (ROC-AUC) and 95% confidence intervals (CIs) for each predictor shown in Panels A and (D) B. (E) Bootstrap ROC-AUC and 95% CIs for each predictor shown in Panels A and (F) B. The dots in Panels C to F represent ROC-AUC values and the horizontal colored bars represent their 95% CIs, enabling a visual comparison of significance among the predictors.

Similar articles

Cited by

References

    1. Kavvoura FK, Owen KR. Maturity onset diabetes of the young: clinical characteristics, diagnosis and management. Pediatr Endocrinol Rev. 2012;10(2):234–242. - PubMed
    1. McDonald TJ, Colclough K, Brown R, Shields B, Shepherd M, Bingley P, et al. Islet autoantibodies can discriminate maturity-onset diabetes of the young (MODY) from Type 1 diabetes. Diabet Med. 2011;28(9):1028–1033. doi: 10.1111/j.1464-5491.2011.03287.x. - DOI - PubMed
    1. Bonnefond A, Unnikrishnan R, Doria A, Vaxillaire M, Kulkarni RN, Mohan V, et al. Monogenic diabetes. 12Nat Rev Dis Prim. 2023;9(1) doi: 10.1038/s41572-023-00421-w. - DOI - PubMed
    1. Laver TW, Wakeling MN, Knox O, Colclough K, Wright CF, Ellard S, et al. Evaluation of Evidence for Pathogenicity Demonstrates That BLK, KLF11, and PAX4 Should Not Be Included in Diagnostic Testing for MODY. Diabetes. 2022;71(5):1128–1136. doi: 10.2337/db21-0844. - DOI - PMC - PubMed
    1. Froguel P, Zouali H, Vionnet N, Velho G, Vaxillaire M, Sun F, et al. Familial hyperglycemia due to mutations in glucokinase. Definition of a subtype of diabetes mellitus. N Engl J Med. 1993;328(10):697–702. doi: 10.1056/NEJM199303113281005. - DOI - PubMed

Supplementary concepts

LinkOut - more resources